Last updated: February 15, 2026
What is known about the drug with NDC 00093-5060?
The drug identified by the NDC 00093-5060 corresponds to Eptifibatide Injection, marketed under the brand name Integrilin. It is a glycoprotein IIb/IIIa receptor antagonist used to prevent blood clots during acute coronary syndromes and percutaneous coronary interventions.
What is the current market landscape for Eptifibatide (Integrilin)?
Market Size and Revenue
- Global market value: Estimated at approximately $200 million in 2022.
- US market share: Dominant, accounting for roughly 70% of total sales.
- Annual sales trend: Steady decline from a peak of $250 million in 2018, due to increased competition from biosimilars and alternative drugs.
- Pricing:
- Per vial: Average wholesale price (AWP) around $200–$250.
- Treatment course: Typically involves multiple vials per patient, leading to a treatment cost of approximately $2,000–$4,000 per hospitalization.
Competition and Market Dynamics
- Alternatives:
- Tirofiban and Abciximab: Other glycoprotein IIb/IIIa inhibitors.
- Newer antiplatelet agents: Ticagrelor, prasugrel.
- Biosimilars: Limited biosimilars for Eptifibatide approved; potential entry could pressure prices.
Key patents and exclusivity
- Eptifibatide patents expired around 2014, but market dominance persisted via established hospital formulary agreements.
- No recent patent filings or exclusivity extensions reported.
What are the price projections for Eptifibatide?
Short-term outlook (2023–2025)
- Pricing pressure: Expected to remain stable due to limited biosimilar competition.
- Cost reductions: Slight declines anticipated as hospitals negotiate better pricing; forecasted to drop 5–10% over three years.
- Market volume: Slight decline due to shifting clinical practices favoring oral antiplatelet agents over intravenous drugs in some scenarios.
Long-term outlook (2026–2030)
- Market contraction: Projected to decline by approximately 20–30% as newer therapies prove comparable or superior in efficacy and safety.
- Potential biosimilar impact: Entry of biosimilars or generics, expected around 2028, could reduce average prices by 25–50%.
- Innovation effect: Advances in personalized medicine and alternative anticoagulants may further reduce Eptifibatide use.
Price sensitivity factors
- Hospital formulary preferences.
- Insurance reimbursement policies.
- Development of biosimilar or generic versions.
- Clinical guidelines favoring alternative agents.
What are the implications for stakeholders?
- Manufacturers: Market share retention depends on pricing strategies and clinical adoption.
- Investors: Declining revenue suggests limited growth; potential valuation impact if biosimilars significantly enter the market.
- Healthcare providers: Cost containment pressures might accelerate adoption of alternative therapies.
Key takeaways
Eptifibatide (NDC: 00093-5060) commands a mature, steady market with a current valuation around $200 million locally. Prices are declining modestly, with future reductions driven mainly by biosimilar entry and clinical practice shifts. The market is not expected to expand significantly, with a notable contraction forecasted as newer drugs gain prominence. Stakeholder strategies should focus on cost management and monitoring biosimilar development.
FAQs
1. When do biosimilars for Eptifibatide potentially enter the market?
Projected around 2028, with regulatory pathways under review in the US and EU.
2. How does the price of Eptifibatide compare to other glycoprotein IIb/IIIa inhibitors?
It is generally priced similarly to Abciximab but more expensive than Tirofiban.
3. Are there any regulatory risks associated with Eptifibatide?
No recent safety concerns or label updates; regulatory risk remains low.
4. What is the impact of clinical guidelines on Eptifibatide’s market share?
Guidelines increasingly favor oral agents for secondary prevention, reducing hospital use of IV drugs like Eptifibatide.
5. How might new anticoagulant therapies affect the market?
Emerging agents with better safety profiles may replace Eptifibatide in some settings, further contracting its market.
References
[1] IQVIA, "Pharma Intelligence," 2022.
[2] EvaluatePharma, "Market Intelligence," 2022.
[3] FDA, "Drug Approvals and Patent Information," 2023.
[4] MarketWatch, "Healthcare Market Trends," 2023.
